TY - JOUR
T1 - Practical management of patients with chronic myeloid leukemia receiving imatinib
AU - Deininger, Michael W.N.
AU - O'Brien, Stephen G.
AU - Ford, John M.
AU - Druker, Brian J.
PY - 2003/4/15
Y1 - 2003/4/15
N2 - The introduction of imetinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has dramatically changed the management of chronic myeloid leukemia (CML). More than 10,000 patients worldwide have been treated with imatinib in clinical trials, and a large body of information has accumulated about the use of this drug. The purpose of this article is to review practical guidelines in regard to optimal dosing, monitoring, managing common side effects such as myelosuppression, and potential drug interactions. The treatment recommendations are intended to optimize therapy with imatinib while taking into account a patient's specific circumstances.
AB - The introduction of imetinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has dramatically changed the management of chronic myeloid leukemia (CML). More than 10,000 patients worldwide have been treated with imatinib in clinical trials, and a large body of information has accumulated about the use of this drug. The purpose of this article is to review practical guidelines in regard to optimal dosing, monitoring, managing common side effects such as myelosuppression, and potential drug interactions. The treatment recommendations are intended to optimize therapy with imatinib while taking into account a patient's specific circumstances.
UR - http://www.scopus.com/inward/record.url?scp=0038518619&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038518619&partnerID=8YFLogxK
U2 - 10.1200/JCO.2003.11.143
DO - 10.1200/JCO.2003.11.143
M3 - Review article
C2 - 12668652
AN - SCOPUS:0038518619
SN - 0732-183X
VL - 21
SP - 1637
EP - 1647
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 8
ER -